Trial Profile
PA-Gemox Regimen Followed by Thalidomide Versus AspaMetDex Regimen in NKTCL Patients a Randomized, Open-label, Phase 3 Study
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 06 Mar 2023
Price :
$35
*
At a glance
- Drugs Dexamethasone (Primary) ; Folinic acid (Primary) ; Gemcitabine (Primary) ; Methotrexate (Primary) ; Oxaliplatin (Primary) ; Pegaspargase (Primary) ; Thalidomide (Primary)
- Indications T-cell lymphoma
- Focus Therapeutic Use
- 12 Mar 2021 Planned End Date changed from 1 Jun 2020 to 31 Dec 2022.
- 12 Mar 2021 Planned primary completion date changed from 1 Apr 2018 to 31 Dec 2022.
- 12 Mar 2021 Status changed from active, no longer recruiting to recruiting.